

A CASE REPORT ON SERRATIOPEPTIDASE INDUCED INTERNAL BLEEDING IN A PATIENT WITH BEHÇET'S ILLNESS

**Dr. P. Venkata Ramana*¹, Thumpera Aravind², S. Ayesha², A. Jayasree² and
C. T. Anjana Devi²**

¹Assistant Professor, Department of Pharmacy Practice, P.Rami Reddy Memorial College of Pharmacy, Kadapa.

²Pharm-D Interns, Department of Pharmacy Practice, P.Rami Reddy Memorial College of Pharmacy, Kadapa.

Article Received on
22 Nov. 2016,

Revised on 12 Dec. 2016,
Accepted on 01 Jan. 2016

DOI: 10.20959/wjpr20172-7671

Corresponding Author*Dr. P. Venkata Ramana**

Assistant Professor,
Department of Pharmacy
Practice, P.Rami Reddy
Memorial College of
Pharmacy, Kadapa.

ABSTRACT

Serratopeptidase is a product of enterobacterium Serratia species which is acting as a proteolytic enzyme. Enterobacterium Serratia species is isolated from the intestine of silkworm. Serratopeptidase is called by several names like serralysin, serratia peptidase, serratiapeptase, Serratopeptidase, or serrapeptidase. A 28-year old Syrian woman with Behçet's Disease was admitted to emergency department with a large number of ecchymotic foci on her body surface. She had a history of Behçet's Disease for 4 years. The patient explained that she had experienced venous thrombosis one year ago, and she also had this disorder edema developed in her legs right after having the venous thrombosis. The patient also said that she was

recommended to use Serratopeptidase continuously to prevent the development of some kind of thrombosis as well as to prevent from having the edema in her legs. Behcet's disease is a multi systemic chronic inflammatory disease. It was first described as a triple complex of recurrent oral ulcers, genital ulcers and uveitis. Vascular thrombosis is a serious issue and it might accompany to the course of Behçet's disease. In controlling vascular thrombosis anticoagulants, antiplatelet or antifibrinolytic agents were not recommended because of the high bleeding risk. While taking these drugs or proteolytic herbal drugs to prevent thrombosis, bleeding risk should be taken into consideration.

KEYWORDS: Behcet's disease, Serratopeptidase, diffuse ecchymotic hemorrhage.

INTRODUCTION

Serratiopeptidase is a product of enterobacterium *Serratia* species which is acting as a proteolytic enzyme. Enterobacterium *Serratia* species is isolated from the intestine of silkworm. Serratiopeptidase is called by several names like serralyisin, *serratia* peptidase, *serratia*peptase, Serratiopeptidase, or serrapeptidase. Major work of Serratiopeptidase is purifying products of inflammatory process and eliminating pus, cysts, arterial plaque, blood clots, scar tissue and hematoma. It is against fibrin make up. Serratiopeptidase can prevent swelling and fluid preservation as an anti-edemic drug. Common side effects are gastric discomfort, nausea, pneumonitis, allergic reaction, and there is increased risk of bleeding when taken the drug with garlic, fish oil and turmeric and other herbal supplements.^[1] This is a case report of Serratiopeptidase induced diffuse ecchymotic hemorrhage with Behçet's disease. Behcet's disease is a multi systemic chronic inflammatory disease. It was first described by in 1937 as a characteristic clinical trial of recurrent oral aphthous ulcers, genital ulcers and uveitis.^[2] Later additional manifestations were described, including joints, skin, vessels, brain, lungs, genitourinary and gastrointestinal disorders^[3] The disease has vascular manifestations which depends on the type and location of the vessel involved^[4] Systemic vasculitis is an important pathological finding in Behcet's disease. Blood vessels of all sizes may be affected, both in venous and arterial systems^[5] In Behcet's disease, venous involvement is usually causes vascular complications. It may result in superficial thrombophlebitis and deep venous thrombosis.^[6] Venous thrombosis can be seen in the early stage of Behçet's disease^[7] Venous thrombosis could be the result of endothelial inflammation.^[8] Rather than giving primary anticoagulation, by controlling systemic inflammation the venous thrombotic events can be prevented.^[9,10] Actually primary anticoagulation is not recommended^[11] Diffuse ecchymotic hemorrhage is extremely rare in Behçet's disease.

CASE REPORT

A 28-year old Syrian woman with Behçet's Disease was admitted to emergency department with a large number of ecchymotic foci on her body surface. She had a history of Behçet's Disease for 4 years. The patient explained that she had experienced venous thrombosis one year ago and she also had this disorder edema developed in her legs right after having the venous thrombosis. The patient also said that she was recommended to use Serratiopeptidase continuously to prevent the development of some kind of thrombosis as well as to prevent from having the edema in her legs. She had a previous history of using azathioprin 100

mg/day, omeprazole 20 mg/day, Serratiopeptidase 20 mg/day as medication. The patient had no prior history of surgical operation and she denied smoking, alcohol and any illicit drug use. On physical examination, her blood pressure was 120/80 mmHg, heart rate 89 beats per minute and regular, respiratory rate 18 per minute, body temperature was 36.2°C. Her cardio-respiratory system was normal, abdomen was soft and non-tender and there was no organomegaly and other systems were also normal. She had ecchymosis varying diameter 3 to 10 cm along her back, abdomen, upper and lower extremities. Those had occurred within 24 hours as mentioned on her history. There was no evidence of gastrointestinal and genitourinary bleeding in patient. On laboratory examination, her blood analysis were as follows: APTT 90 second, PT undetectable, platelet 523.000/ μ L, hemoglobin 12 gm/dL, leukocyte 18.300/ μ L, Creatinin 0.4 mg/dL, BUN 14 mg/dL, sodium 139 mEq/L, potassium 4.1 mEq/L, AST 15 U/L, ALT 15 U/L, total protein 6.5 gm/dL, albumin 4.2 gm/dL, glucose 84 mg/dL, calcium 9.4 mg/dL, phosphorus 3.8 mg/dL, LDH 152 U/L. The peripheral blood smear was evaluated as a normal. In addition, urine and stool microscopy, C-reactive protein, erythrocyte sedimentation rate, rheumatoid factor, serum iron, serum iron binding capacity, ferritin, vitamin B12, folic acid levels were normal. Fecal occult blood was negative. The patient's chest radiography, electrocardiography and abdominopelvic ultrasonography were normal.

DISCUSSION

Behcet's disease is a multi systemic chronic inflammatory disease. It was first described as a triple complex of recurrent oral ulcers, genital ulcers and uveitis. Our patient's history fulfilled the proposed criteria of the international study group for Behcet's disease.^[12] The pathogenesis of thrombotic tendency in patients with Behcet's disease is not well known. Venous thrombosis could be the result of endothelial inflammation^[13] also endothelial cell ischemia or disruption that leads to enhancement of platelet aggregation is accused^[14] Other possible causes of thrombotic process are the anti phospholipid antibodies and elevated von Willebrand factor antigen levels have been demonstrated^[15] Thromboses of the large vessels are related to a poor prognosis. Arterial occlusions and aneurysms are associated with the presence of venous thromboses^[16] Studies showed that anti-coagulant treatment is not effective in preventing venous thrombosis^[17] Rather than giving primary anticoagulation, by controlling systemic inflammation the venous thrombotic events can be prevented^[18,19] Anticoagulants, antiplatelet or antifibrinolytic agents are not recommended in management of deep vein thrombosis associated with Behcet's disease^[20] Our patient was receiving a

proteolytic enzyme called Serratiopeptidase which was against fibrin build up. She was receiving this proteolytic enzyme uncontrolled. This drug has no specific follow up laboratory test and it might increase the likelihood of bleeding. Her coagulation parameters were deteriorated and she also had diffuse ecchymotic bleeding. Since diffuse ecchymotic hemorrhage is extremely rare in Behçet's disease, we believe that her bleeding situation was because of the Serratiopeptidase intake. We have given fresh frozen plasma and vitamin-K in order to control the bleeding. Repeated controls of coagulation parameters had indicated that the coagulation tests became normal. During follow-up ecchymosis had been resolved.

CONCLUSION

Vascular thrombosis is a serious issue and it might accompany to the course of Behçet's disease. In controlling vascular thrombosis anticoagulants, antiplatelet or antifibrinolytic agents were not recommended because of the high bleeding risk. While taking these drugs or proteolytic herbal drugs to prevent thrombosis, bleeding risk should be taken into consideration.

REFERENCES

1. Behçet H. Über rezidiverende aphtose, durch ein Virus verursachte Geschwure am Mund, am Auge und den Genitalien. *Derm Wochenschr*, 1937; 36: 1152-1157.
2. Wechsler B, Lê Thi H, Amoura Z: Behçet's disease. *Rev Prat*, 2005 55: 239-246.
3. Louali FE, Tamdy A, Soufiani A, Oukerraj L, Omari D, Bounjoum F, Mekouar F, Tazi-Mezalek Z, Bouhouch R, Zarzur J, Cherti M. Cardiac thrombosis as a manifestation of Behçet syndrome. *Tex Heart Inst J*. 2010; 37(5): 568-571.
4. Seyahi E, Yurdakul S. Behçet's Syndrome and Thrombosis. *Mediterr J Hematol Infect Dis*. 2011; 3(1): e2011026.
5. Schirmer M, Calamia KT. Is there a place for large vessel disease in the diagnostic criteria for Behçet's disease. *J Rheumatol*, 1999; 26: 2511-2512.
6. Kuzu MA, Ozaslan C, Koksoy C, Gurler A & Tuzuner A. Vascular involvement in Behcet's disease: 8-year audit. *World Journal of Surgery*, 1994; 18: 948-953.
7. Seyahi E, Melikoglu M, Yazici H. Clinical features and diagnosis of Behcet's syndrome. *Int J Adv Rheumatol*, 2007; 5: 8.
8. Barnes CG. Treatment of Behcet's syndrome. *Rheumatology (Oxford)*. 2006; 45(3): 245-247.

9. Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M et al. Vascular involvement in Behçet's Disease: a retrospective analysis of 2319 cases. *Int J Dermatol*, 2006; 45: 919-921.
10. Mader R, Ziv M, Adawi M, Mader R & Lavi I. (1999) Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease. *J Rheumatol*, 26: 2404 - 2408.
11. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain A M, Gul A, Houman M H, Kotter I, Olivieri I, Salvarani C, Sfikakis P, Siva A, Stanford M R, Stubiger N, Yurdakul S, Yazici H. EULAR recommendations for the management of Behcet disease. *Ann Rheum Dis*. 2008; 67: 1656-1662.
12. Nakahama K, Yoshimura K, Marumoto R, Kikuchi M and Lee IS, Hase T, Matsubara H. Cloning and sequencing of *Serratia* protease gene. *Nucleic Acids Res*. 1986; 14(14): 5843-5855.
13. Wikipedia.Serratiopeptidase.02.04.2013.In:<http://en.wikipedia.org/wiki/Serratiopeptidase>.
14. International Study Group for Behçet's disease: Criteria for diagnosis of Behçet's disease. *Lancet*, 1990; 335: 1078-1080.
15. Vayá A, Forner MJ, Estellés A, Villa P, Mira Y, Ferrando F, García Fuster JM, Oliver V, Aznar J. *Haematologica*, 2000; 85: 425-428.
16. Louali FE, Tamdy A, Soufiani A, Oukerraj L, Omari D, Bounjoum F, Mekouar F, Tazi-Mezalek Z, Bouhouch R, Zarzur J, Cherti M. Cardiac thrombosis as a manifestation of Behçet Syndrome. *Tex Heart Inst J*. 2010; 37(5): 568-571.
17. Hammami S, Mahjoub S, Ben-Hamda K, Brahem R, Gamra H, Ben Farhat M. Intracardiac Thrombus in Behçet's disease: two case reports. *Thromb J*. 2005; 3: 9.
18. Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behcet's Syndrome: a report of 24 cases. *British Journal of Rheumatology*, 1994; 33: 48-51.
19. Kahraman O, Celebi-Onder S, Kamali S et al. Long-term course of deep venous thrombosis in Patients with Behçet's disease. *Arthritis Rheum*, 2003; 48(9): S385.
20. Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus Anticoagulation. *Clin Rheumatol*. 2008; 27: 201-205.